Characteristics and findings in principal clinical trials carried out with anti‐HER2 mAbs, ICIs, Akt inhibitors, poly‐ADB ribose polymerase (PARP) inhibitors, and CDK inhibitors as first line therapy in advanced breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.